DuoResp Spiromax: new formoterol/budesonide inhaler

DuoResp Spiromax (formoterol/budesonide) has been launched for use in adults with asthma or chronic obstructive pulmonary disease (COPD), where use of an inhaled corticosteroid and a long-acting beta2 agonist is appropriate.

DuoResp Spiromax 160/4.5 and DuoResp Spiromax 320/9 are therapeutically equivalent to Symbicort Turbohaler 200/6 and Symbicort Turbohaler 400/12, respectively.
DuoResp Spiromax 160/4.5 and DuoResp Spiromax 320/9 are therapeutically equivalent to Symbicort Turbohaler 200/6 and Symbicort Turbohaler 400/12, respectively.

The breath-actuated dry powder inhaler is available in two strengths:

  • 160/4.5 (formoterol fumarate dihydrate 6 microgram, budesonide 200 microgram per dose) - equivalent to Symbicort 200/6 Turbohaler
  • 320/9 (formoterol fumarate dihydrate 12 microgram, budesonide 400 microgram per dose) - equivalent to Symbicort 400/12 Turbohaler

In asthma, the 160/4.5 inhaler may be used both as regular maintenance treatment and as needed in response to symptoms. The 320/9 inhaler must be used with a separate reliever.

In COPD, both inhalers are indicated for symptomatic treatment in patients with a forced expiratory volume in one second (FEV1) <50% predicted normal and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

The Spiromax device has a design similar to that of pressurised metered-dose inhalers. There are three steps to using the inhaler: open, breathe and close. No priming is required. Dose confirmation is provided by a 'click' sound, lactose taste and a dose indicator.

View DuoResp Spiromax drug entry

Further information: Teva UK

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...